Biltricide
What is this? Biltricide is a medicine with praziquantel. It treats infections caused by flukes (tiny worms).
What's happening? There is less Biltricide available now. Other similar medicines can be used instead.
Does this affect me? If you take Biltricide, your supply may be limited. Ask your doctor or pharmacist for help.
What should I do? Do not stop taking your medicine without advice. Talk to your pharmacist or doctor about other options.
🤖 Ce résumé en langage clair est généré automatiquement à partir de l'avis officiel de l'agence à l'aide de l'IA. Il est fourni à titre d'information générale uniquement — il ne s'agit pas de conseils médicaux. Pour toute décision concernant votre santé, consultez toujours un pharmacien ou un médecin et lisez la source officielle liée ci-dessous.
📋 De l'avis officiel de l'agence
Mis à jour il y a 1 semaine- Première publication
- 26/08/2025
- Médicaments concernés
- Biltricide
- Points forts affectés
- 600 mg film-coated tablets
- Statut de pénurie
- Ongoing
- Zone thérapeutique (MeSH)
- Trematode Infections
- Début de pénurie d'approvisionnement
- 26/08/2025
- Disponibilité des alternatives
- Yes
- Dénomination commune internationale (DCI) ou nom commun
- praziquantel
Contenu de la page
Information sur la pénurie
There is a shortage of Biltricide in the European Union/European Economic Area (EU/EEA).
Biltricide contains the active substance praziquantel and is used for the treatment of infections caused by trematodes (parasitic worms).
The company informed EMA that it is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine. This has led to a shortage of Biltricide in the EU.
The shortage is not related to a quality defect of the product or a safety issue.
The shortage affects all Member States where the product is marketed: Germany, France and the Netherlands. Other countries that import Biltricide are also affected.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party supports the MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- The company that markets Biltricide is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU. This has led to a shortage of the medicine in the EU.
- For patients with a trematode infection other than schistosomiasis, healthcare professionals should consider alternative treatment options.
- For patients with schistosomiasis, there is no other effective treatment available in the EU. Healthcare professionals should consult local or national guidelines on how to manage these patients.
- For additional information consult your country’s shortage register or contact your national competent authority.
- The company that markets Biltricide, a medicine used to treat certain parasitic (worm) infections, is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU.
- Other treatments are available for most parasitic infections; your doctor will discuss with you the best alternative treatment option.
- There is no treatment alternative for schistosomiasis in the EU; your doctor will manage your condition in line with relevant guidelines.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Raison de la pénurie
The company informed EMA that it is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine. This has led to a shortage of Biltricide in the EU.
The shortage is not related to a quality defect of the product or a safety issue.
États membres concernés
The shortage affects all Member States where the product is marketed: Germany, France and the Netherlands. Other countries that import Biltricide are also affected.
Surveillance des pénuries
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party supports the MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Recommandations pour les professionnels de santé
- The company that markets Biltricide is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU. This has led to a shortage of the medicine in the EU.
- For patients with a trematode infection other than schistosomiasis, healthcare professionals should consider alternative treatment options.
- For patients with schistosomiasis, there is no other effective treatment available in the EU. Healthcare professionals should consult local or national guidelines on how to manage these patients.
- For additional information consult your country’s shortage register or contact your national competent authority.
Recommandations pour les patients et les aidants
- The company that markets Biltricide, a medicine used to treat certain parasitic (worm) infections, is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU.
- Other treatments are available for most parasitic infections; your doctor will discuss with you the best alternative treatment option.
- There is no treatment alternative for schistosomiasis in the EU; your doctor will manage your condition in line with relevant guidelines.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Points clés
- Medicines affected
- Biltricide
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- praziquantel
- Therapeutic area (MESH)
- Trematode Infections
- Strengths affected
- 600 mg film-coated tablets
- Availability of alternatives
- Yes
Dates clés
- Start of supply shortage
- First published
Informations médicales connexes
🔬 Détails médicaux / techniques (pour les professionnels)
INN: praziquantel · Strengths: 600 mg film-coated tablets · Area: Trematode Infections · Alternatives: Yes
Toutes les informations de cette page proviennent de l'avis officiel de l'agence. Nous les traduisons et les résumons ; nous n'ajoutons ni ne modifions les faits.
